COMMUNIQUÉS West-GlobeNewswire

Solid Biosciences to Present at Upcoming Scientific Meetings
01/10/2025
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from [...]
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19
01/10/2025
- Meeting date aligns with prior guidance - - FDA to review AEON’s analytical development plan and initial data - IRVINE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: [...]
SRx Health Solutions Appoints Joshua Epstein to Board of Directors and Compensation Committee
01/10/2025
TAMPA, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the appointment of Joshua Epstein to the Board of Directors and Compensation Committee. [...]
Sanara MedTech to Report Third Quarter 2025 Financial Results on November 12, 2025
01/10/2025
FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2025
CLEVELAND, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
01/10/2025
BROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented [...]
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
01/10/2025
Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional U.S. government [...]
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
01/10/2025
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of newly diagnosed [...]
Spur Therapeutics to Present New Clinical Data on Its Gene Therapy Candidate in Gaucher Disease at Upcoming ESGCT Annual Congress
01/10/2025
LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced it will present new clinical data for avigbagene parvec (FLT201), its Phase 3-ready gene therapy candidate for Gaucher disease, at the European [...]
Comphya Announces First Patient Implanted with CaverSTIM in U.S. Pilot Study at Johns Hopkins University School of Medicine
01/10/2025
Pilot study evaluates safety and tolerability of implantable neuromodulation therapy for erectile dysfunction following radical prostatectomy LAUSANNE, Switzerland, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Comphya SA, a [...]
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
01/10/2025
NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two [...]
Athernal Bio Launches with £3.5 Million Funding from Delin Ventures
01/10/2025
Cambridge, UK, October 1, 2025 – Athernal Bio today announced its official launch alongside £3.5 million funding from founding investor Delin Ventures. The company is focused on the development of targeted [...]
Tessellate Bio Appoints Katie Chapman as Chief Scientific Officer
01/10/2025
NAARDEN, the Netherlands and STEVENAGE, United Kingdom, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, today announces the [...]
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
01/10/2025
Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]
Inventiva annonce la nomination d’Andrew Obenshain au poste de Directeur Général
01/10/2025
Daix (France), New York City (New York, Etats-Unis), le 1 er octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
01/10/2025
If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Decision based on positive data [...]
Patient-Led NM Launches Statewide Summits and Video Campaign to Spotlight New Mexico’s Healthcare Crisis
01/10/2025
A Call for New Mexicans to Demand Policy Reform That Secures Timely Access to High-Quality Care Santa Fe, NM, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Patient-Led NM today announced the launch of a series of Healthcare [...]
Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases
01/10/2025
Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional payments for other indications; includes contingent R&D investment, tiered sales royalties, and a [...]
NMDP Surpasses $100 Million Comprehensive Campaign Goal to Expand Patient Access, Remove Financial Barriers to Life-saving Transplants
01/10/2025
The announcement, made at the 18th annual NMDP Gala in Minneapolis, represents significant philanthropic support of the organization’s mission to save lives through cell therapy MINNEAPOLIS, Sept. 30, 2025 (GLOBE [...]

Pages